ETOP IBCSG Partners Foundation is particularly proud that the IBCSG 22-00 study contributed to CATALINA, the first large-scale, independent validation of AI-based tumor-infiltrating lymphocyte (TIL) assessment across seven randomized clinical trials in triple-negative breast cancer. Computational TIL scores provided robust prognostic information even when deployed as locked models without retraining, representing a major step toward scalable and reproducible immune biomarker assessment.

A tremendous collaborative effort, made possible by the vision and leadership of Roberto Salgado, Stefan Michiels, Sherene Loi, and colleagues across the international TILs Working Group.

Congratulations to everyone involved in these remarkable studies.

Read here:

Podcast with Professor Sherene Loi: https://open.spotify.com/episode/3ocASFqDiay9ePTC9FHSfs?si=54459b73347c49a3